Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Leukemia
,
Venetoclax
Venetoclax Added to Cladribine plus Low-Dose Ara-C Alternating with 5-Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Read More
Leukemia
MBG453 in Combination with Hypomethylating Agents in Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Read More
Leukemia
,
Venetoclax
Phase 2 Study of CPX-351 plus Venetoclax in Patients with Acute Myeloid Leukemia
Read More
Leukemia
,
Venetoclax
Decitabine + Venetoclax Compared with Intensive Chemotherapy in AML: A Propensity Score–Matched Analysis
Read More
Leukemia
,
Venetoclax
Venetoclax + Azacitidine versus Azacitidine Alone in Treatment-Naïve Patients with AML Ineligible for Intensive Therapy
Read More
Leukemia
Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory IDH1-Mutated AML
Read More
Leukemia
Health-Related Quality of Life with Oral Azacitidine (CC-486) in Patients with Acute Myeloid Leukemia in First Remission After Induction Chemotherapy
Read More
Leukemia
Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated AML
Read More
Leukemia
Addition of Enasidenib to Azacitidine Improves Response versus Azacitidine Alone in Mutant IDH2 Newly Diagnosed Acute Myeloid Leukemia
Read More
Leukemia
Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine-131-Apamistamab in Patients with Active R/R AML Results in Donor Hematopoietic Cell Engraftment
Read More
120
121
122
123
124
125
126
Page 123 of 198
Results 1221 - 1230 of 1974
